Mechanism of Inhibitory Effect of Dextran Sulfate and Heparin on Replication of Human Immunodeficiency Virus in Vitro

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1988 Aug 1

PMID 2457906

Citations 104

Authors

M Baba

R Pauwels

J Balzarini

J Arnout

J Desmyter

E De Clercq

Affiliations

Soon will be listed here.

Abstract

The sulfated polysaccharides dextran sulfate and heparin have proved to be potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) in vitro. Dextran sulfate (Mr 5000) and heparin (Mr 15,000) completely protected MT-4 cells against HIV-1-induced cytopathogenicity at a concentration of 25 micrograms/ml. Their 50% inhibitory concentrations were 9.1 micrograms/ml (dextran sulfate) and 7.0 micrograms/ml (heparin), respectively. No toxicity for the host cells was observed with these compounds at a concentration of 625 micrograms/ml. The anti-HIV-1 activity of heparins of various molecular weights correlated well with their anticoagulant activity. On the other hand, with dextran sulfates of low molecular weight (5000, 8000) a significant inhibitory effect on HIV-1 was achieved at a concentration that was not markedly inhibitory to the blood coagulation process. Dextran sulfate and heparin were not inhibitory to HIV-1 reverse transcriptase unless they were used at concentrations in excess of those that inhibited HIV-1 replication. They were highly effective against HIV-1 replication even when present only during the 2-hr virus adsorption period. Studies using radiolabeled HIV-1 virions indicated that dextran sulfate and heparin inhibit virus adsorption to the host cells.

Citing Articles

Progress in Nanotechnology for Treating Ocular Surface Chemical Injuries: Reflecting on Advances in Ophthalmology.

Qi Q, Su D, Zhuang S, Yao S, Heindl L, Fan X Adv Sci (Weinh). 2025; 12(6):e2407340.

PMID: 39755928 PMC: 11809354. DOI: 10.1002/advs.202407340.

EPS T14 from Prevents Infection of Human Nasal Epithelial Cells by Respiratory Viruses.

Pezzino G, Calabro A, Drommi F, Campana S, Cavaliere R, Bonaccorsi I Immunotargets Ther. 2024; 13:487-499.

PMID: 39364227 PMC: 11446858. DOI: 10.2147/ITT.S470319.

Selected Milestones in Antiviral Drug Development.

De Clercq E Viruses. 2024; 16(2).

PMID: 38399945 PMC: 10891914. DOI: 10.3390/v16020169.

Preventative and therapeutic potential of animal milk components against COVID-19: A comprehensive review.

Singh P, Hernandez-Rauda R, Pena-Rodas O Food Sci Nutr. 2023; 11(6):2547-2579.

PMID: 37324885 PMC: 10261805. DOI: 10.1002/fsn3.3314.

Dextran sulfate from B512F exerts potent antiviral activity against SARS-CoV-2 and .

Andreu S, von Kobbe C, Delgado P, Ripa I, Buzon M, Genesca M Front Microbiol. 2023; 14:1185504.

PMID: 37206325 PMC: 10189130. DOI: 10.3389/fmicb.2023.1185504.

References

Refsum N, Collen D, GODAL H, Janson T, Mannucci P, Nilsson I . Sensitivity and precision of activated partial thromboplastin time (APTT) methods. A multicenter study. Scand J Haematol. 1978; 20(1):89-95. DOI: 10.1111/j.1600-0609.1978.tb01559.x. View

Sasaki S, Takemoto T, Oka S . TOXICITY OF HEPARINOIDS, WITH SPECIAL REFERENCE TO THE PRECIPITATION OF FIBRINOGEN. Thromb Diath Haemorrh. 1964; 12:232-61. View

Balzarini J, De Clercq E, Torrence P, Mertes M, Park J, Schmidt C . Role of thymidine kinase in the inhibitory activity of 5-substituted-2'-deoxyuridines on the growth of human and murine tumor cell lines. Biochem Pharmacol. 1982; 31(6):1089-95. DOI: 10.1016/0006-2952(82)90347-1. View

Gallo R, SARIN P, Gelmann E, Robert-Guroff M, Richardson E, Kalyanaraman V . Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science. 1983; 220(4599):865-7. DOI: 10.1126/science.6601823. View

Barre-Sinoussi F, Chermann J, Rey F, Nugeyre M, Chamaret S, Gruest J . Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983; 220(4599):868-71. DOI: 10.1126/science.6189183. View

Folkman J, Langer R, Linhardt R, Haudenschild C, Taylor S . Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science. 1983; 221(4612):719-25. DOI: 10.1126/science.6192498. View

Hoylaerts M, Owen W, Collen D . Involvement of heparin chain length in the heparin-catalyzed inhibition of thrombin by antithrombin III. J Biol Chem. 1984; 259(9):5670-7. View

Levy J, Hoffman A, Kramer S, Landis J, Shimabukuro J, Oshiro L . Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science. 1984; 225(4664):840-2. DOI: 10.1126/science.6206563. View

Mitsuya H, Guo H, Cossman J, Megson M, Reitz Jr M, Broder S . Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I). Science. 1984; 225(4669):1484-6. DOI: 10.1126/science.6206569. View

10.

Harada S, Koyanagi Y, Yamamoto N . Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science. 1985; 229(4713):563-6. DOI: 10.1126/science.2992081. View

11.

Broder S, Yarchoan R, Collins J, Lane H, Markham P, Klecker R . Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet. 1985; 2(8456):627-30. DOI: 10.1016/s0140-6736(85)90002-9. View

12.

Yarchoan R, Klecker R, Weinhold K, Markham P, Lyerly H, Durack D . Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986; 1(8481):575-80. DOI: 10.1016/s0140-6736(86)92808-4. View

13.

Balzarini J, Mitsuya H, De Clercq E, Broder S . Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. Biochem Biophys Res Commun. 1986; 136(1):64-71. DOI: 10.1016/0006-291x(86)90877-6. View

14.

Dawes J, Bara L, Billaud E, Samama M . Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis. 1986; 16(2):116-22. DOI: 10.1159/000215281. View

15.

De Clercq E . Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS). J Med Chem. 1986; 29(9):1561-9. DOI: 10.1021/jm00159a001. View

16.

Furman P, Fyfe J, St Clair M, Weinhold K, Rideout J, Freeman G . Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986; 83(21):8333-7. PMC: 386922. DOI: 10.1073/pnas.83.21.8333. View

17.

Ueno R, Kuno S . Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine. Lancet. 1987; 1(8546):1379. DOI: 10.1016/s0140-6736(87)90681-7. View

18.

Naggi A, Torri G, Casu B, Pangrazzi J, Abbadini M, Zametta M . "Supersulfated" heparin fragments, a new type of low-molecular weight heparin. Physico-chemical and pharmacological properties. Biochem Pharmacol. 1987; 36(12):1895-900. DOI: 10.1016/0006-2952(87)90485-0. View

19.

Fischl M, Richman D, GRIECO M, Gottlieb M, Volberding P, Laskin O . The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317(4):185-91. DOI: 10.1056/NEJM198707233170401. View

20.

Richman D, Fischl M, GRIECO M, Gottlieb M, Volberding P, Laskin O . The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317(4):192-7. DOI: 10.1056/NEJM198707233170402. View